KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EPS (Basic) (2016 - 2026)

Pacific Biosciences Of California has reported EPS (Basic) over the past 16 years, most recently at -$0.13 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 750.0% year-over-year to -$0.13; the TTM value through Dec 2025 reached -$1.84, down 62.83%, while the annual FY2025 figure was -$1.82, 61.06% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.13 at Pacific Biosciences Of California, roughly flat from -$0.13 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.02 in Q4 2024 and troughed at -$1.44 in Q1 2025.
  • A 5-year average of -$0.35 and a median of -$0.31 in 2023 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): tumbled 4600.0% in 2021 and later soared 106.45% in 2024.
  • Year by year, EPS (Basic) stood at -$0.33 in 2021, then fell by 12.12% to -$0.37 in 2022, then rose by 16.22% to -$0.31 in 2023, then skyrocketed by 106.45% to $0.02 in 2024, then plummeted by 750.0% to -$0.13 in 2025.
  • Business Quant data shows EPS (Basic) for PACB at -$0.13 in Q4 2025, -$0.13 in Q3 2025, and -$0.14 in Q2 2025.